Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies

Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials

(2014) Matteo Monami et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study

(2014) Hsin-Chun Chou et al.   DRUG SAFETY

Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment

(2014) Amy G. Egan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

(2014) L. Li et al.   BMJ-British Medical Journal

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study

(2014) J.-L. Faillie et al.   BMJ-British Medical Journal

A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks

(2013) M. A. Nauck   DIABETES CARE

A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs

(2013) D. Funch et al.   DIABETES OBESITY & METABOLISM

Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials

(2013) M. Monami et al.   DIABETES OBESITY & METABOLISM

American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement

(2013) Alan Garber et al.   Endocrine Practice

Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes

(2013) William B. White et al.   NEW ENGLAND JOURNAL OF MEDICINE

Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus

(2013) Benjamin M. Scirica et al.   NEW ENGLAND JOURNAL OF MEDICINE

Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?

(2013) D. Cohen   BMJ-British Medical Journal

Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study

(2013) D. T. Eurich et al.   BMJ-British Medical Journal

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study

(2013) Carlo B Giorda et al.   Lancet Diabetes & Endocrinology

Safety and Tolerability of Sitagliptin in Type 2 Diabetes: Pooled Analysis of 25 Clinical Studies

(2013) Samuel S. Engel et al.   Diabetes Therapy

Liraglutide-associated acute pancreatitis

(2012) E. Knezevich et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer

(2012) Carlos Alves et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Exenatide Therapy and the Risk of Pancreatitis and Pancreatic Cancer in a Privately Insured Population

(2012) John A. Romley et al.   Diabetes Technology & Therapeutics

Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study

(2012) M. Wenten et al.   DIABETIC MEDICINE

A cohort study of acute pancreatitis in relation to exenatide use

(2011) D. D. Dore et al.   DIABETES OBESITY & METABOLISM

Vildagliptin-Induced Acute Pancreatitis

(2011) Christian Girgis et al.   Endocrine Practice

Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies

(2011) Michael Elashoff et al.   GASTROENTEROLOGY

Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin: A retrospective observational pharmacy claims analysis

(2010) R. Garg et al.   DIABETES CARE

Observational studies: going beyond the boundaries of randomized controlled trials

(2010) Wenying Yang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide

(2009) David D. Dore et al.   CURRENT MEDICAL RESEARCH AND OPINION

Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes: A retrospective cohort study

(2009) R. A. Noel et al.   DIABETES CARE

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2008) D. M. Nathan et al.   DIABETES CARE

Selective Reporting of Adjusted Estimates in Observational Epidemiology Studies: Reasons and Implications for Meta-analyses

(2008) Jaime Peters et al.   EVALUATION & THE HEALTH PROFESSIONS

Exenatide and Rare Adverse Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis

(2008) Debora Williams-Herman et al.   BMC Endocrine Disorders